Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics
Authors
Keywords
-
Journal
EBioMedicine
Volume 76, Issue -, Pages 103856
Publisher
Elsevier BV
Online
2022-02-11
DOI
10.1016/j.ebiom.2022.103856
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2021) Obbina Abani et al. LANCET
- Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
- (2021) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19
- (2021) Kun Li et al. mBio
- Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia
- (2020) Ning Tang et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
- (2020) Markus Hoffmann et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy
- (2020) Sukbin Jang et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia
- (2020) Songping Cui et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Thromboelastography Profiles of Critically Ill Patients With Coronavirus Disease 2019
- (2020) Eugene Yuriditsky et al. CRITICAL CARE MEDICINE
- Comparative analysis of antiviral efficacy of FDA‐approved drugs against SARS‐CoV‐2 in human lung cells
- (2020) Meehyun Ko et al. JOURNAL OF MEDICAL VIROLOGY
- Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
- (2020) Divij Mathew et al. SCIENCE
- The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner
- (2020) Mizuki Yamamoto et al. Viruses-Basel
- Coagulation abnormalities and thrombosis in patients with COVID-19
- (2020) Marcel Levi et al. Lancet Haematology
- Comprehensive mapping of immune perturbations associated with severe COVID-19
- (2020) Leticia Kuri-Cervantes et al. Science Immunology
- Functional testing of tranexamic acid effects in patients undergoing elective orthopaedic surgery
- (2020) Philipp Groene et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics
- (2018) Li Di CURRENT DRUG METABOLISM
- Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay
- (2016) Mizuki Yamamoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk
- (2015) Ji-Young Choi et al. MEDICINE
- TEG and ROTEM: Technology and clinical applications
- (2013) David Whiting et al. AMERICAN JOURNAL OF HEMATOLOGY
- A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimized solid-phase extraction and ESI-MS detection: more accurate evaluation for pharmacokinetic study
- (2008) Yan-guang Cao et al. ANALYTICAL AND BIOANALYTICAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search